Category: biotech

.Monopar Therapies is actually recuperating a drug from the scrap heap of AstraZeneca’s uncommon ailment pipe. It has licensed ALXN-1840, an applicant for the procedure

.AstraZeneca has used expert system to develop a distinct biomarker for its own Daiichi Sankyo-partnered datopotamab deruxtecan (Dato-DXd), planning to differentiate the antibody-drug conjugate (ADC)

.AN2 Therapies is re-thinking its business in response to dull midphase data, promising to lay off half its own staff members as well as quit

.ALX Oncology’s phase 2 gastric cancer cells response price has deteriorated. After seeing its own CD47 blocker simply hammered management over the initial one-half of

.After more than two decades of work with neurodegenerative diseases, Swiss biotech hvac Immune system cases it might have an activity changer on its own